Company Overview of Targazyme, Inc.
Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...
3200 County Road 104
Floresville, TX 78114
Founded in 2005
Key Executives for Targazyme, Inc.
Co-Founder, Chairman and Chief Executive Officer
Co-Founder and Vice President of Manufacturing
Co-Founder and Vice President of Research
Senior Vice President of Regulatory Affairs & Quality Assurance
Senior Vice President of Development
Compensation as of Fiscal Year 2014.
Targazyme, Inc. Key Developments
Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use with Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
Feb 11 15
Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TZ101 to prevent and reduce the severity and
incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant. GVHD is a serious, life-threating complication of stem cell transplantation. Orphan drug status confirms the importance of Targazyme's novel treatment approach to prevent and reduce the incidence and severity of GVHD in
patients with blood cancers where stem cell transplant is prescribed. TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD, which occurs in a large percentage of these patients and is very difficult to manage clinically.
Targazyme, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014
Aug 6 14
Targazyme, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.
TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board
Jun 3 14
TargaZyme, Inc. announced that it has appointed Christopher Calhoun to its Business Advisory Board. Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries